Microsampling Approach for Monitoring of Kinase Inhibitor Targeted Therapies
- Conditions
- Blood Concentrations of Nine Anti-cancer Drugs : Axitinib, Olaparib, regorafénib, Cabozantinib, Niraparib, Talazoparib, Palbociclib, Abemaciclib, Tucatinib
- Registration Number
- NCT05598788
- Lead Sponsor
- Rennes University Hospital
- Brief Summary
The MISTIK project aims at clinically validating the technique of oral anticancer drugs determination by volumetric absorptive micro-sampling and at comparing the results to measurements performed on venous samples.
- Detailed Description
The International recommendations for the validation of DBS-based methods will be applied (Capiau et al, TDM, 2019) by including 40 patients per molecule of interest. Nine drugs will be monitored : axitinib, olaparib, regorafénib, cabozantinib, niraparib, talazoparib, palbociclib, abemaciclib, tucatinib.
Two samples will be collected from each patient, one by venous sampling and the second at the same time (approximately) using a capillary blood sample derived from a finger prick.
Recruitment & Eligibility
- Status
- RECRUITING
- Sex
- All
- Target Recruitment
- 360
- Patients treated with one of the 9 drugs concerned by the study : axitinib, olaparib, regorafénib, cabozantinib, niraparib, talazoparib, palbociclib, abemaciclib, tucatinib
- person who does not object to their participation in the research
- Adults subject to legal protection (safeguard of justice, curatorship, guardianship), persons deprived of their liberty
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Comparison of venous blood vs VAMS concentrations 1 day Comparison of drug concentrations measured from the venous blood samples with concentrations measured from VAMS
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (3)
Rennes University Hospital
🇫🇷Rennes, France
Centre Eugène Marquis Unicancer
🇫🇷Rennes, France
Institut de cancérologie Strasbourg Europe
🇫🇷Strasbourg, France